Novartis business deals across mergers & acquisitions, business development & licensing were summarized for investors at 2024 J.P. Morgan Healthcare conference. This video highlights the scale and strategic focus of over $6bn of deals in 2023 by our CEO Vas Narasimhan. It provides examples of how our we are strengthening portfolios and how AI advancements in drug development moves are creating a stronger company for the future. **This video uses audio from the webcasted event.** J.P. Morgan Healthcare Conference Event Date: January 08, 2024 Full webcast here: https://go.novartis.social/49012mq Full presentation here: https://go.novartis.social/3SzISTc Novartis JPM HC 2024 Coverage: https://go.novartis.social/48T3StR Investor Relations: https://go.novartis.social/3SCtnKp Investor Events: https://go.novartis.social/3vWoP8M Novartis Strategy: https://go.novartis.social/42iv0jr Disclaimer: J.P. Morgan Healthcare Conference live event contains forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: https://go.novartis.social/3SzISTc The J.P. Morgan Healthcare conference live event also contains non-IFRS measures. An explanation of non-IFRS measures can be found on our website https://go.novartis.social/4bk6cM3. Learn more: https://go.novartis.social/48T3StR

 448      2